Alnylam Pharmaceuticals Inc. (ALNY)

76.91
0.52 0.68
NASDAQ : Health Technology
Prev Close 76.39
Open 76.58
Day Low/High 75.70 / 77.94
52 Wk Low/High 60.27 / 124.22
Volume 648.60K
Avg Volume 927.90K
Exchange NASDAQ
Shares Outstanding 110.98M
Market Cap 8.36B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2018 and reviewed recent commercial and R&D highlights.

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the Phase 1 study of givosiran, an investigational, subcutaneous RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues For ONPATTRO® (patisiran) And Provides Additional Commercial Updates

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues For ONPATTRO® (patisiran) And Provides Additional Commercial Updates

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today pre-announced its unaudited fourth quarter 2018 global net product revenues for ONPATTRO and provided additional updates on the product's commercial launch.

Alnylam To Webcast Presentation At 37th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 37th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.

Alnylam Announces Settlement Of Litigation With Silence Therapeutics

Alnylam Announces Settlement Of Litigation With Silence Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics.

Alnylam Provides R&D Updates And Announces 2019 Product And Pipeline Goals At R&D Day

Alnylam Provides R&D Updates And Announces 2019 Product And Pipeline Goals At R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announces it is hosting its R&D Day in New York City today.

Alnylam To Webcast R&D Day

Alnylam To Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Company's website, www.

DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc.

Vir Biotechnology And Alnylam Pharmaceuticals Initiate Phase 1/2 Study Of VIR-2218

Vir Biotechnology And Alnylam Pharmaceuticals Initiate Phase 1/2 Study Of VIR-2218

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc.

DEADLINE MONDAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

DEADLINE MONDAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc.

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) For Potential Breaches Of Fiduciary Duties

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) For Potential Breaches Of Fiduciary Duties

Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors.

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28,...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc.

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results For Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results For Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic,...

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2018 and reviewed recent commercial and R&D highlights.

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 10:15 am...

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.

Alnylam To Webcast Conference Call Discussing Third Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.

Alnylam Expands Alnylam Act® Program To Improve Diagnosis Of Primary Hyperoxaluria Type 1 (PH1) And Aligns With FDA On Trial Design For ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran

Alnylam Expands Alnylam Act® Program To Improve Diagnosis Of Primary Hyperoxaluria Type 1 (PH1) And Aligns With FDA On Trial Design For ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has expanded the Alnylam Act ® program to include no-charge, third-party genetic testing and counseling for adults and children who may have...

Alnylam Announces Advocacy For Impact Grants To Inspire Unique Solutions That Address Unmet Needs Affecting The Rare Disease Community

Alnylam Announces Advocacy For Impact Grants To Inspire Unique Solutions That Address Unmet Needs Affecting The Rare Disease Community

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Advocacy for Impact Grants, a global competitive grants program that aims to inspire patient advocacy groups to develop solutions to address...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc.

Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr.